JP2018516984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516984A5 JP2018516984A5 JP2018513745A JP2018513745A JP2018516984A5 JP 2018516984 A5 JP2018516984 A5 JP 2018516984A5 JP 2018513745 A JP2018513745 A JP 2018513745A JP 2018513745 A JP2018513745 A JP 2018513745A JP 2018516984 A5 JP2018516984 A5 JP 2018516984A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hpv
- composition according
- item
- rnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 53
- 101710163270 Nuclease Proteins 0.000 claims description 34
- 241000701806 Human papillomavirus Species 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 16
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 16
- 108020005004 Guide RNA Proteins 0.000 claims description 13
- 108091033409 CRISPR Proteins 0.000 claims description 11
- 210000002510 keratinocyte Anatomy 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 10
- 101150071673 E6 gene Proteins 0.000 claims description 8
- 101150013359 E7 gene Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 229920006317 cationic polymer Polymers 0.000 claims description 3
- 239000002082 metal nanoparticle Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000002073 nanorod Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 2
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000010459 TALEN Methods 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- -1 cationic lipid Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168188P | 2015-05-29 | 2015-05-29 | |
| US62/168,188 | 2015-05-29 | ||
| PCT/US2016/034627 WO2016196282A1 (en) | 2015-05-29 | 2016-05-27 | Compositions and methods for cell targeted hpv treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516984A JP2018516984A (ja) | 2018-06-28 |
| JP2018516984A5 true JP2018516984A5 (OSRAM) | 2019-06-27 |
Family
ID=56137529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513745A Pending JP2018516984A (ja) | 2015-05-29 | 2016-05-27 | 細胞を標的にしたｈｐｖ処置のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20160346360A1 (OSRAM) |
| EP (1) | EP3324999A1 (OSRAM) |
| JP (1) | JP2018516984A (OSRAM) |
| CA (1) | CA3000155A1 (OSRAM) |
| GB (1) | GB2543873A (OSRAM) |
| WO (1) | WO2016196282A1 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP3919505B1 (en) | 2013-01-16 | 2023-08-30 | Emory University | Uses of cas9-nucleic acid complexes |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| GB2543873A (en) * | 2015-05-29 | 2017-05-03 | Agenovir Corp | Compositions and methods for cell targeted HPV treatment |
| US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
| CA2999922A1 (en) * | 2015-09-29 | 2017-04-06 | Agenovir Corporation | Delivery methods and compositions |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| JP7588390B2 (ja) | 2016-10-14 | 2024-11-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基エディターのａａｖ送達 |
| WO2018118585A1 (en) * | 2016-12-22 | 2018-06-28 | Agenovir Corporation | Antiviral compositions |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US20180201921A1 (en) * | 2017-01-18 | 2018-07-19 | Excision Biotherapeutics, Inc. | CRISPRs |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| WO2018175502A2 (en) * | 2017-03-21 | 2018-09-27 | Shuber Anthony P | Treating cancer with cas endonuclease complexes |
| BR112019019655A2 (pt) | 2017-03-23 | 2020-04-22 | Harvard College | editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico |
| EP3601568A1 (en) * | 2017-03-31 | 2020-02-05 | Agenovir Corporation | Antiviral therapeutic |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942042A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20230044432A1 (en) * | 2019-12-03 | 2023-02-09 | Université de Liège | Pooled Crispr Inverse PCR Sequencing (PCIP-Seq): Simultaneous Sequencing of Viral Insertion Points and the Integrated Viral Genomes with Long Reads |
| CN111018956B (zh) * | 2019-12-30 | 2020-10-09 | 鼓润(武汉)医疗科技有限公司 | 一种靶向敲除hpv urr基因的dna结合蛋白、系统及其应用 |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN113952475B (zh) * | 2021-09-27 | 2025-03-11 | 中国人民解放军陆军军医大学 | 淋巴细胞和介导crispr系统的纳米复合物联合在制备治疗宫颈癌药物中的应用 |
| CN116004716A (zh) * | 2022-09-09 | 2023-04-25 | 华中农业大学 | 一种复制型dCas9-FokI系统进行高效基因编辑的方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5580571A (en) | 1991-10-15 | 1996-12-03 | Hostetler; Karl Y. | Nucleoside analogues |
| SE9200951D0 (sv) | 1992-03-27 | 1992-03-27 | Kabi Pharmacia Ab | Pharmaceutical composition containing a defined lipid system |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| EP0702516A4 (en) | 1993-06-01 | 1998-04-22 | Life Technologies Inc | GENETIC IMMUNIZATION WITH CATIONIC LIPIDS |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Ｄｎａ認識のための結合タンパク質におけるまたはそれに関連する改良 |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| JP5266210B2 (ja) | 2006-05-25 | 2013-08-21 | サンガモ バイオサイエンシズ インコーポレイテッド | 改変開裂ハーフドメイン |
| US20110023144A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| BR112015013784A2 (pt) * | 2012-12-12 | 2017-07-11 | Massachusetts Inst Technology | aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas |
| DK3553174T3 (da) | 2012-12-17 | 2025-08-04 | Harvard College | Rna-guided modificering af humant genom |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US9885033B2 (en) | 2013-03-15 | 2018-02-06 | The General Hospital Corporation | Increasing specificity for RNA-guided genome editing |
| WO2014165349A1 (en) * | 2013-04-04 | 2014-10-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
| EP3011030B1 (en) * | 2013-06-17 | 2023-11-08 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| KR102829712B1 (ko) * | 2013-08-29 | 2025-07-10 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물 |
| US9526784B2 (en) * | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| CA2930015A1 (en) * | 2013-11-07 | 2015-05-14 | Editas Medicine, Inc. | Crispr-related methods and compositions with governing grnas |
| SG11201606819QA (en) * | 2014-02-18 | 2016-09-29 | Univ Duke | Compositions for the inactivation of virus replication and methods of making and using the same |
| WO2015153889A2 (en) * | 2014-04-02 | 2015-10-08 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
| AU2015266770A1 (en) * | 2014-05-30 | 2016-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
| WO2016196283A1 (en) * | 2015-05-29 | 2016-12-08 | Agenovir Corporation | Antiviral methods and compositions |
| WO2016196273A1 (en) * | 2015-05-29 | 2016-12-08 | Agenovir Corporation | Compositions and methods to treat viral infections |
| GB2543873A (en) * | 2015-05-29 | 2017-05-03 | Agenovir Corp | Compositions and methods for cell targeted HPV treatment |
-
2016
- 2016-05-27 GB GB1609438.5A patent/GB2543873A/en not_active Withdrawn
- 2016-05-27 JP JP2018513745A patent/JP2018516984A/ja active Pending
- 2016-05-27 CA CA3000155A patent/CA3000155A1/en not_active Abandoned
- 2016-05-27 EP EP16730570.5A patent/EP3324999A1/en not_active Withdrawn
- 2016-05-27 US US15/166,936 patent/US20160346360A1/en not_active Abandoned
- 2016-05-27 WO PCT/US2016/034627 patent/WO2016196282A1/en not_active Ceased
-
2018
- 2018-12-18 US US16/224,591 patent/US20190201501A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516984A5 (OSRAM) | ||
| JP2018516983A5 (OSRAM) | ||
| US20230167425A1 (en) | Rna guided eradication of varicella zoster virus | |
| EP3417062B1 (en) | Excision of retroviral nucleic acid sequences | |
| US9981020B2 (en) | Methods and compositions for RNA-guided treatment of HIV infection | |
| JP2017518075A5 (OSRAM) | ||
| US20190010518A1 (en) | Compositions and Methods of Delivering Treatments for Latent Viral Infections | |
| CN108883201A (zh) | Rna指导的治疗hiv感染的方法和组合物 | |
| JP2019512458A (ja) | Ｒｎａによって誘導された、ヒトｊｃウイルス及び他のポリオーマウイルスの根絶 | |
| WO2016150336A1 (zh) | 一种CRISPR-Cas9系统及其制备方法和应用 | |
| WO2018112470A1 (en) | Co-delivery of nucleic acids for simultaneous suppression and expression of target genes | |
| CN105518149A (zh) | 靶细胞内治疗性蛋白的靶向产生的系统和方法 | |
| Avila et al. | Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules | |
| Abbaszadeh-Goudarzi et al. | Targeted delivery of CRISPR/Cas13 as a promising therapeutic approach to treat SARS-CoV-2 | |
| CN118973610A (zh) | 通过中断细胞和病毒受体相互作用来阻断asfv感染的方法 | |
| JP2020505390A (ja) | Ｃｒｉｓｐｒ治療薬を送達するためのウイルスベクターとしてのレンチウイルスおよび非組み込みレンチウイルス | |
| JP2008531672A5 (OSRAM) | ||
| Zuo et al. | Nuclear‐Targeting Delivery of CRISPRa System for Upregulation of β‐Defensin against Virus Infection by Dexamethasone and Phenylalanine Dual‐Modified Dendrimer | |
| Tan et al. | CRISPR/Cas9-Mediated Genome Editing: Current Status | |
| Dev et al. | Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics: CRISPR/Cas9 in antiviral therapeutics | |
| Kundu et al. | Developing New Molecular-Targeted Therapeutics,‘from Gene to Drug' | |
| Nunes | Development of cationic polymeric nanoparticles for plasmid DNA vaccine delivery | |
| Anvar et al. | HR9 cell-penetrating peptide: An effective delivery approach of gene editing vectors for tumor treatment | |
| Dev et al. | Letters in Animal Biology | |
| HK40000290A (en) | Excision of retroviral nucleic acid sequences |